At the news
? NEUTRALIMPACT 4/10 PRESS-RELEASE filed Aug 10, 2026 at 07:00 ET
Grifols announced completion of the clinical portion (last patient, last visit) of its Phase 3 SPARTA trial evaluating Prolastin-C in alpha-1 antitrypsin deficiency patients with emphysema. Topline results are expected by the end of 2026. This is a pipeline milestone with no financial data or efficacy readout yet.
- SPARTA Phase 3 trial completed last-patient-last-visit; topline results expected by end of 2026.
- Trial enrolled 345 participants across 37 sites in 16 countries.
- Evaluates two dose regimens of Prolastin-C (60 mg/kg and 120 mg/kg) vs placebo over three years.
- Primary endpoint is whole-lung CT densitometry, a sensitive measure of emphysema progression.
Before · The news · First close · A day later · A week later
Replay the market's reaction
Step through every 5 minutes around the news, then see how it compares with similar events.
Subscribe for Full Access